Skip to main content

Ardais Expands Aventis Collaboration

NEW YORK, April 6 (GenomeWeb News) - Ardais today said that it has extended a research collaboration with Aventis that the companies began in 2002.

Under the terms of the original collaboration, Aventis was granted access to Ardais' BIGR (Biomaterials and Information for Genomic Research) library of clinical data and biomaterials. Under the expanded agreement, Ardais will use this platform in combination with immunohistochemistry profiling "to assess the potential of certain biological targets in the pharmaceutical company's R&D pipeline."

Ardais said it would use its technology to optimize validation assays and assist in the characterization of targets in panels of normal and diseased human tissues.

Financial terms of the agreement were not disclosed.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.